Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Dr. Timothy Rebbeck Receives the 2020 ASCO-ACS Award

Dr. Timothy Rebbeck Receives the 2020 ASCO-ACS Award

This year's ASCO-ACS (American Society of Clinical Oncology – American Cancer Society) Award was presented to Dr. Timothy Rebbeck. ASCO-ACS gave this award to an individual who has made significant contributions to cancer prevention and control research and practice.

Dr. Rebbeck is a professor of cancer prevention and epidemiology at the Harvard T.H. Chan School of Public Health.

He is also a professor of medical oncology at Dana-Farber Cancer Institute. Dr. Rebbeck's research focuses on the causes of cancer and cancer prevention. The genetic causes of cancer and the effects of racial differences on mortality rates are particular areas of interest to him.

A Deep Look into Cancer Genetics

In an interview with ASCO Daily News, Dr. Rebbeck made the following statement: “My work involves identifying people at risk of cancer and factors that predict whether those cancers will have an aggressive clinical course. We also work on either screening for cancer or interventions to prevent it before cancer develops.” he explained.

Dr. Rebbeck leads studies of cancer causes, prevention, outcomes, healthcare inequalities and global health problems using molecular epidemiology. His work has improved understanding of environmental and genetic factors in breast, prostate, skin, myeloma, endometrial and ovarian cancers, leading to the development of interventions to reduce the burden of these cancers in individuals and communities.

An international cancer alliance founded and led by Dr. Rebbeck studies cancer risks and outcomes in carriers of BRCA1/BRCA2 mutations. “We are carrying out some hereditary studies around the BRCA1 and BRCA2 genes, which are very strong indicators of cancer risk and prognosis in ovarian, breast and prostate cancers.” says Dr. Rebbeck.

RELATED TOPICS 

A second consortium under his leadership also focuses on men of African ancestry with prostate cancer in North America and Africa. Prostate cancer is known to have a more aggressive course in this patient group. The consortium studies how to identify men at high risk of prostate cancer and predict the measures needed to reduce mortality. This large network in the United States and Africa works in several areas of prostate cancer: genetic susceptibility, tumor biomarkers and tumor genomics.

Dr. Rebbeck said, “Some of our studies focus on prostate cancer, and some involve precise measures based on biological knowledge to deliver specific interventions – the right person at the right time – so that we do not overtreat men whose prostate cancers do not have aggressive biology, but instead focus on treating cancers that are more likely to be lethal.” African American men are the group at greatest risk in prostate cancer and have a higher rate of aggressive disease than other groups. Dr. Rebbeck said, “That is why we spend so much time ensuring that African American men in particular receive optimal cancer screening, intervention and treatment; no other racial group of men has a higher mortality rate than African American men.”

Dr. Rebbeck and his team also study problems that prevent access to cancer prevention practices (see The 10 golden rules of cancer prevention). They conduct pilot projects to understand how high-tech tools, usually available only at specialized medical centers, can reach populations receiving inadequate medical care.

Dr. Rebbeck says, “The issue is not only getting patients to a clinic that has all these tools, but also ensuring that every part of society is represented in clinical research and precision medicine”

“A Complex and Multifaceted Approach Is Needed for Early Detection and Prevention of Cancers” Dr. Rebbeck

HPV vaccination and community-based approaches such as high taxes on cigarettes are effective in preventing some cancers. However, much more comprehensive and individualized approaches are needed for other cancers and particular circumstances, such as increased familial risk.

Dr. Rebbeck says, “We want to go deeper into genetic testing or risk assessment to identify people at high risk and discover and implement specialized interventions that may help prevent cancer in these people” and adds: “Cancer prevention can limit adverse cancer outcomes and deaths. We do not want to increase the complexity by intervening excessively. We have to find the right balance, and genomic information may help us with this.”

Sources

Dr. Timothy Rebbeck to Receive the 2020 ASCO-ACS Award.
dailynews.ascopubs.org - 20 may 2020

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Dr. Timothy Rebbeck Receives the 2020 ASCO-ACS Award

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy